Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy

@article{Sthr2007LacosamideAN,
  title={Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy},
  author={Thomas St{\"o}hr and Harvey J. Kupferberg and James P. Stables and Daeock Choi and Robert H. Harris and Harold L Kohn and Nancy Y. Walton and H. Steve White},
  journal={Epilepsy Research},
  year={2007},
  volume={74},
  pages={147-154}
}
This paper comprises a series of experiments in rodent models of partial and generalized epilepsy which were designed to describe the anti-convulsant profile of the functionalized amino acid lacosamide. Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice. The… 
The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents.
TLDR
The present results identify for the first time, an anxiolytic potential of lacosamide in a conditioned emotional response (CER) model in rat, and the mouse marble burying assay.
Current understanding of the mechanism of action of the antiepileptic drug lacosamide
TLDR
Lacosamide is the only known antiepileptic drug in clinical practice that exerts its anticonvulsant activity predominantly by selectively enhancing slow sodium channel inactivation.
A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice
TLDR
The results of these studies indicate that PH192 protects against both chemically‐ and electrically‐induced seizures with little central nervous system side effects, suggesting that the oxazolidinone pharmacophore has potential for discovering new antiepileptic drugs with possibly minimal central side effects.
Evaluation of Anticonvulsant Actions of Dibromophenyl Enaminones Using In Vitro and In Vivo Seizure Models
TLDR
While AK6 had no effect on locomotion in rats, phenytoin significantly decreased locomotion and may be excellent candidates for further investigation as potential agents for the treatment of epilepsy syndromes with possibly less CNS side effects.
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
TLDR
Experimental data suggest anticonvulsant as well as analgesic effects in LCM, and the most common adverse events are unspecific central nervous system and gastrointestinal effects such as dizziness, vertigo, nausea, and headache.
Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model.
TLDR
The combination of LCM with LTG and PB produced additive interaction in the mouse tonicclonic seizure model, despite various molecular mechanisms of action of the tested AEDs.
The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus
TLDR
The results presented here suggest that lacosamide deserves investigation for the clinical treatment of SE, and potential for disease modification in this rat model of self-sustaining SE will require further studies.
Lacosamide Reduces Seizure Severity but Increases Seizure Frequency in PTZ-Kindled Rats
TLDR
Lacosamide showed a convincing anticonvulsant action in the win-PTZ kindling model of epilepsy by preventing the generalization of seizures.
Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property
TLDR
Comparison to efficacious doses from the seizure tests support the view that there may be a better separation with the newer AEDs, and somewhat similar effects of phenytoin, valproate, pregabalin and lacosamide on attention and reaction time are highlighted.
Developing novel antiepileptic drugs: Characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models
TLDR
The results of the present investigation suggest that NAX 5055 is a first-in-class neurotherapeutic for the treatment of epilepsy in patients refractory to currently approved antiepileptic drugs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Animal Models Used in the Screening of Antiepileptic Drugs
Summary: The identification of potential therapeutic agents for the treatment of epilepsy requires the use of seizure models. These models can be either in vivo or in vitro, mechanism specific,
Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy
TLDR
A comparison of the pharmacology of chronic models with models of acute (reactive or provoked) seizures in previously healthy (non-epileptic) animals demonstrates that drug testing in chronic models of epilepsy yields data which are more predictive of clinical efficacy and adverse effects, so that chronic models should be used relatively early in drug development to minimize false positives.
Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test.
TLDR
It is more difficult to prevent experimental "psychomotor" seizures with drugs than to elevate the threshold for minimal electroshock seizures, and drugs ineffective in psychomotor epilepsy rank higher than does Phenurone, an agent acknowledged to be superior in the management of this disorder.
Seeking a mechanism of action for the novel anticonvulsant lacosamide
TLDR
Evidently LCM perturbs excitability in primary cortical cultures but does not appear to do so via a high-affinity interaction with an acknowledged recognition site on a target for existing antiepileptic drugs.
Valproic acid treatment of experimental status epilepticus
TLDR
It is predicted that a serum concentration of around 270 micrograms/ml VPA would be required for control of generalized convulsive status epilepticus in human patients, and the safety of this high a concentration of VPA has not been tested.
Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro
TLDR
It is concluded that lacosamide blocks 4-AP induced epileptiform activity in the visual cortex and appears to inhibit epileptogenesis (seizure spread) by interacting with a stereoselective, but as yet unidentified, target site in rodent neocortex in the mid-micromolar range.
Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine
TLDR
The potential clinical efficacy of tiagabine for control of status epilepticus was evaluated in an experimental model and an abnormal, hypo-reactive behavioral state which was accompanied by an EEG pattern of high-amplitude, frontally dominant, rhythmic, 3-5-Hz spike-wave activity was observed.
Experimental secondarily generalized convulsive status epilepticus induced by d,l-homocysteine thiolactone
Secondarily generalized convulsive status epilepticus was induced by intraperitoneal (i.p.) injection of D,L-homocysteine thiolactone to rats with actively epileptogenic cobalt lesions in motor
Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs
  • H. White
  • Chemistry, Medicine
    Epilepsia
  • 1999
TLDR
The multiple mechanisms of action associated with FBM, TPM, ZNS, GBP, and perhaps LTG, and the unique modulation of GABA levels by VGB and TGB are likely to account for the anticonvulsant efficacy of these newer AEDs in patients with epilepsy.
The new antiepileptic drugs: clinical applications.
TLDR
The general practitioner is familiarized with the appropriate roles and effective uses of the new antiepileptic drugs in specific clinical scenarios to aid in prescribing the most appropriate medication.
...
1
2
3
...